A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer

A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer
Conditions: Gastrointestinal Cancer; Gastrointestinal Neoplasms; Colorectal Cancer; Colorectal Neoplasms; Colorectal Carcinoma; Gastric Cancer; Gastric Neoplasm; KRAS Mutation-Related Tumors; CRC; Colorectal Cancer Metastatic

Interventions: Drug: ompenaclid; Drug: FOLFIRI; Drug: Bevacizumab; Drug: FOLFOX regimen

Sponsors: Inspirna, Inc.

**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

May 16, 2024Comments OffClinicalTrials.gov | Gastroenterology Clinical Trials | Gastroenterology Studies | US National Library of Medicine
Comments